[
  {
    "ts": null,
    "headline": "PRESS DIGEST-British Business - June 23",
    "summary": "June 23 - The following are the top stories onthe business pages of British newspapers. Reuters has notverified these stories and does not vouch for their accuracy. The...",
    "url": "https://finnhub.io/api/news?id=5632ffd6ea4aafcc6a7fa7c020b061360a4aeef820be928bf77d46f1210ea507",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750631772,
      "headline": "PRESS DIGEST-British Business - June 23",
      "id": 135468117,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "June 23 - The following are the top stories onthe business pages of British newspapers. Reuters has notverified these stories and does not vouch for their accuracy. The...",
      "url": "https://finnhub.io/api/news?id=5632ffd6ea4aafcc6a7fa7c020b061360a4aeef820be928bf77d46f1210ea507"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Eli Lilly and Company - Special Call",
    "summary": "Presenter SpeechMike Czapar All right. Well, good evening, everybody. Thank you for joining us. I know it's probably been a long conference already, but we're very happy to host you here tonight at...",
    "url": "https://finnhub.io/api/news?id=cc8c23cc544cc69f5a13011d985c488a243dda06c929f8a51acc8799c696ba0d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750630825,
      "headline": "Transcript : Eli Lilly and Company - Special Call",
      "id": 135468059,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Presenter SpeechMike Czapar All right. Well, good evening, everybody. Thank you for joining us. I know it's probably been a long conference already, but we're very happy to host you here tonight at...",
      "url": "https://finnhub.io/api/news?id=cc8c23cc544cc69f5a13011d985c488a243dda06c929f8a51acc8799c696ba0d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction com",
    "url": "https://finnhub.io/api/news?id=74a9d5328157cdd6061961f70c3ce9851acb780082ec8a972ddb16b46513c38b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750617060,
      "headline": "Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials",
      "id": 135473108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction com",
      "url": "https://finnhub.io/api/news?id=74a9d5328157cdd6061961f70c3ce9851acb780082ec8a972ddb16b46513c38b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results",
    "summary": "Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients, which aligns with a 7% share price increase over the last month. This, along with new offerings for Zepbound and strategic collaborations, potentially supported the company's stock performance. While the broader market showed a flat trajectory, the company's developments likely added weight to...",
    "url": "https://finnhub.io/api/news?id=524bf072964605f76cb01cb38e77ebd6d5fb5e9aaf6d720eb6005c7129211b03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750612324,
      "headline": "Eli Lilly (NYSE:LLY) Advances Orforglipron GLP-1 Therapy To Phase 3 With Positive Results",
      "id": 135473109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) recently announced positive Phase 3 trial results for orforglipron, the first oral small molecule GLP-1 receptor agonist showing superior A1C reduction in type 2 diabetes patients, which aligns with a 7% share price increase over the last month. This, along with new offerings for Zepbound and strategic collaborations, potentially supported the company's stock performance. While the broader market showed a flat trajectory, the company's developments likely added weight to...",
      "url": "https://finnhub.io/api/news?id=524bf072964605f76cb01cb38e77ebd6d5fb5e9aaf6d720eb6005c7129211b03"
    }
  }
]